HLN:NYE-Haleon plc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 11.35

Change

+0.02 (+0.18)%

Market Cap

USD 50.16B

Volume

0.02B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 72.38B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 44.08B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.96B
ELAN Elanco Animal Health

N/A

USD 6.42B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.54B
BHC Bausch Health Companies Inc

N/A

USD 1.73B
YCBD cbdMD Inc

N/A

USD 8.19M
CPHI China Pharma Holdings Inc

N/A

USD 7.24M
EBS Emergent Biosolutions Inc

N/A

N/A
PRGO Perrigo Company PLC

N/A

N/A

ETFs Containing HLN

CUIK:XETRA 4.38 % 0.00 %

N/A

N/A
UKSRT:SW UBS (Irl) ETF plc - MSCI .. 3.90 % 0.00 %

N/A

USD 0.01B
UKSRE:SW UBS (Irl) ETF plc - MSCI .. 3.68 % 0.00 %

N/A

USD 0.09B
UKSR:SW UBS (Irl) ETF plc - MSCI .. 3.68 % 0.00 %

N/A

USD 0.68B
XASX:XETRA Xtrackers - Xtrackers MSC.. 3.58 % 0.00 %

N/A

N/A
ESIH:LSE iShares MSCI Europe Healt.. 3.02 % 0.00 %

N/A

USD 0.79B
STWX:SW SPDR® MSCI Europe Health.. 2.69 % 0.00 %

N/A

USD 0.66B
FPXE:LSE First Trust IPOX® Europe.. 2.69 % 0.00 %

N/A

USD 1.04M
CSPE:LSE SPDR® MSCI Europe Consum.. 2.44 % 0.00 %

N/A

N/A
SXDPEX:SW iShares STOXX Europe 600 .. 2.39 % 0.00 %

N/A

USD 0.44B
FPXE First Trust IPOX Europe E.. 0.00 % 0.00 %

N/A

USD 4.36M
UKSR:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.00 %

N/A

USD 0.68B
XSDR:LSE Xtrackers MSCI Europe Hea.. 0.00 % 0.00 %

N/A

USD 0.21B
STW:PA SPDR® MSCI Europe Health.. 0.00 % 0.00 %

N/A

USD 0.66B
DXSK:F Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

N/A
EXV4:F 0.00 % 0.00 %

N/A

N/A
SPYC:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

N/A

N/A
DXSE:XETRA Xtrackers - Stoxx Europe .. 0.00 % 0.00 %

N/A

USD 0.14B
EXV4:XETRA iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

USD 0.70B
SPYC:XETRA SPDR® MSCI Europe Consum.. 0.00 % 0.00 %

N/A

N/A
FT1K:LSE Amundi MSCI UK IMI SRI PA.. 0.00 % 0.00 %

N/A

N/A
C1U:PA Amundi FTSE 100 UCITS 0.00 % 0.00 %

N/A

USD 0.04B
ESIS:F Ishares VI PLC - Ishares .. 0.00 % 0.00 %

N/A

N/A
ESIS:XETRA iShares MSCI Europe Consu.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.97% 87% B+ 92% A
Dividend Return 1.22% 67% D+ 49% F
Total Return 20.20% 88% B+ 93% A
Trailing 12 Months  
Capital Gain 34.48% 87% B+ 92% A
Dividend Return 1.99% 43% F 38% F
Total Return 36.46% 87% B+ 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.31% 60% D- 72% C
Dividend Return 10.96% 60% D- 69% C-
Total Return 0.65% 29% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 12.80% 87% B+ 69% C-
Risk Adjusted Return 85.58% 93% A 90% A-
Market Capitalization 50.16B 91% A- 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.